BIOVOX funding news – Germany-based BIOVOX Secures €2.2 Million in Seed Funding

With this financing, BIOVOX will be able to quickly develop and produce its line of cutting-edge bioplastic products, which are intended to completely transform the healthcare sector.

Plastics used in healthcare alone are accountable for carbon emissions equal to the combined emissions of Denmark or Sweden. The healthcare sector accounts for 4.4% of the world's greenhouse gas emissions.

Read also - La Solive funding news – French-based La Solive Secures €4 Million in a Series A Round Funding

In order to maintain high standards of hygiene and affordable prices, sterile single-use medical products are necessary. However, the healthcare system cannot continue to rely on a linear economy based on fossil fuels, as this would go beyond the bounds of a healthy planet and ultimately result in more health issues.

As a solution to this pressing problem of a high-carbon linear economy in healthcare, BIOVOX has created the first medical-grade bioplastics that are sustainable for use in devices and packaging. The business manufactures and distributes sustainable, biocompatible plastics that satisfy the strictest current and future regulatory requirements.

Developed and produced under BIOVOX's ISO 13485-certified medical quality management system, these cutting-edge materials are bio-based, biocompatible, and have a 50–85% lower lifespan carbon footprint than traditional virgin fossil plastics.

The bioplastics offered by BIOVOX are intended for use in a variety of medical, pharmaceutical, and laboratory applications. These applications include packaging, endoscopic equipment, surgical instruments, and consumables. The materials are of the highest caliber and ensure patient safety because they adhere to the strictest regulatory criteria.

With the help of recently raised capital, BIOVOX, led by its founders and chief executive officers, Julian Lotz, CTO, and Carmen Rommel, COO, is able to grow its operations by building a proprietary technical center and adding more personnel to its customer success and sales teams.

Dr.-Ing. Julian Lotz, CEO of BIOVOX GmbH said, “With the support of our new and existing investors, we will scale the organisation to cater to all the customers currently waiting for our sustainable materials. Our pioneering products have already created a strong brand and a rich pipeline. Now we have the financial means to support our customers even better in developing a more environment friendly product range ready for the circular economy. Let’s create full traction for sustainable healthcare plastics,”.

Tilmann Petersen, Investment Manager at HTGF, added: “With BIOVOX, we are funding a team of visionaries whose technological brilliance and deep understanding of regulatory affairs are revolutionising the development of sustainable plastics for the life sciences industry. Not only do they speak the customers’ language, but they have validated their solutions through numerous successful pilot projects and have already brought a product to market. Their contribution to reducing the carbon footprint in healthcare will be immense and we at HTGF are proud to support such a technology for a better environment and make it commercially successful.”

About BIOVOX

Established in 2021, BIOVOX is a leader in the sustainable healthcare industry, establishing benchmarks for bioplastic substances derived from sustainable resources. BIOVOX is collaborating with over 50 clients, including numerous market leaders in the medical device industry, to provide environmentally friendly healthcare solutions. A customer has already used BIOVOX materials to launch their first product.